Discover how MannKind Corp achieved significant financial and operational milestones, setting a strong pace for 2024.

Q1 2024 Earnings Call Transcript May 8, 2024 MannKind Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good ...

Afrezza ® net revenue for the first quarter of 2024 increased $2.0 million, or 16%, compared to the same period in 2023 as a result of higher price (including a decrease in gross-to-net adjustments).

He's majoring in aerospace engineering. He said that while on campus, his Afrezza inhalation powder is perfect. "You can fit it in your pocket and carry it around,” Jones said. But, he said he ...

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product. The number of ...

MannKind (MNKD) surged to a 52-week high of $11.11 on Thursday on high volume as the impending July 15 date for FDA approval of the company's inhaled insulin drug Afrezza approaches. MannKind ...